Ensoma operates in the biotechnology sector, focusing on developing advanced in vivo treatments that utilize DNA editing to engineer immune cells for curative therapies. The company serves healthcare providers and patients, particularly those suffering from diseases that can be treated through genetic engineering of the hematopoietic system. Ensoma's business model revolves around leveraging its proprietary technology platform, Engenious, which combines innovative delivery mechanisms with a comprehensive DNA editing toolkit. This allows for precise engineering of immune cells, offering a one-time treatment solution that aims to cure diseases from within the body. Ensoma generates revenue through partnerships with healthcare institutions and top-tier investors who support its bold vision of pioneering a new kind of medicine. The company operates primarily in the United States but has a global outlook, aiming to transform the landscape of curative therapies through its cutting-edge technology.

Keywords: DNA editing, in vivo treatments, immune cells, curative therapies, hematopoietic system, biotechnology, healthcare, genetic engineering, Engenious platform, top-tier investors.